Head-to-head evidence
Chiglitazar vs Lanifibranor
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: PPAR (pan-agonist) · full Type 2 Diabetes pipeline
Chiglitazar · Bilessglu
Developed by Chipscreen Biosciences
NCT02173457 · Phase 3 · completed
In this randomized, double-blind, active-controlled Phase 3 trial, 740 patients with type 2 diabetes were randomized to chiglitazar (32mg or 48mg) or sitagliptin. At 24 weeks, chiglitazar met its non-inferiority margin against sitagliptin on HbA1c reduction, with very small treatment differences of -0.04 and -0.08 percentage points.
Next expected readout: October 2026 · NCT07511010 (registry estimate)
Lanifibranor
Developed by Inventiva
NCT05232071 · Phase 2 · completed
This trial was randomized, blinded, and placebo-controlled, and its posted results showed lanifibranor and lanifibranor-plus-empagliflozin both significantly lowered HbA1c versus placebo at 24 weeks. However, the trial enrolled only 39 patients across three arms, explicitly designed as an early proof-of-concept study, which is too small to serve as strong, confirmatory evidence on its own.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Chiglitazar's landscape · Lanifibranor's landscape